AZ’s Tagrisso wins new NSCLC first-line approval in EuropeAstraZeneca has widened the licence for its cancer drug Tagrisso (osimertinib) in Europe after regulators gave it the Share XAZ’s Tagrisso wins new NSCLC first-line approval in Europehttps://pharmaphorum.com/news/az-tagrisso-nsclc-egfr-europe/
